Published in J Urol on January 01, 1998
Prophylactic antibiotics after urodynamics in women: a decision analysis. Int Urogynecol J Pelvic Floor Dysfunct (2006) 0.86
Is increased prostatic urethral angle related to lower urinary tract symptoms in males with benign prostatic hyperplasia/lower urinary tract symptoms? Korean J Urol (2012) 0.86
The usefulness of antibiotic prophylaxis in invasive urodynamics in postmenopausal female subjects. Int Urogynecol J Pelvic Floor Dysfunct (2008) 0.85
Pain and embarrassment associated with urodynamic testing in women. Int Urogynecol J (2013) 0.83
Review on ultrasound measurement of bladder or detrusor wall thickness in women: techniques, diagnostic utility, and use in clinical trials. World J Urol (2013) 0.82
Noninvasive urodynamic evaluation. Int Neurourol J (2012) 0.81
Bladder outlet obstruction in men with acute urinary retention: an urodynamic study. World J Urol (2013) 0.80
A novel intraurethral device diagnostic index to classify bladder outlet obstruction in men with lower urinary tract symptoms. Adv Urol (2008) 0.78
Bladder Wall Thickness is Associated with Responsiveness of Storage Symptoms to Alpha-Blockers in Men with Lower Urinary Tract Symptoms. Korean J Urol (2012) 0.78
Patient perceptions of physical and emotional discomfort related to urodynamic testing: a questionnaire-based study in men and women with and without neurologic conditions. Urology (2015) 0.77
Assessment of noninvasive predictors of bladder outlet obstruction and acute urinary retention secondary to benign prostatic enlargement. Arab J Urol (2011) 0.75
Does uroflowmetry parameter facilitate discrimination between detrusor underactivity and bladder outlet obstruction? Investig Clin Urol (2016) 0.75
Imaging assessments of lower urinary tract dysfunctions: Future steps. Turk J Urol (2014) 0.75
Defining the degree of intravesical prostatic protrusion in association with bladder outlet obstruction. Korean J Urol (2013) 0.75
Noninvasive methods of diagnosing bladder outlet obstruction. Indian J Urol (2009) 0.75
Trained and dedicated staff appears to be the main factor in decreasing anxiety and improving overall satisfaction during urodynamic testing: A prospective, randomized trial. Can Urol Assoc J (2016) 0.75
Changes in bladder wall thickness and detrusor wall thickness after surgical treatment of benign prostatic enlargement in patients with lower urinary tract symptoms: a preliminary report. Korean J Urol (2014) 0.75
Ultrasound detrusor wall thickness measurement in combination with bladder capacity can safely detect detrusor underactivity in adult men. World J Urol (2016) 0.75
Association of increased urine brain derived neurotrophic factor with lower urinary tract symptoms in men with benign prostatic hyperplasia. J Huazhong Univ Sci Technolog Med Sci (2017) 0.75
How painful is multichannel urodynamic testing? Int Urogynecol J Pelvic Floor Dysfunct (2009) 0.75
Is multichannel urodynamic assessment necessary before considering a surgical treatment of BPH? Pros and cons. World J Urol (2015) 0.75
Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol (2001) 2.87
Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol (2001) 2.83
Heat versus drugs in the treatment of benign prostatic hyperplasia. BJU Int (2003) 2.05
Percutaneous stone manipulation. J Urol (1981) 2.00
Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol (2000) 1.94
Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey. Int J Clin Pract (2007) 1.88
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol (1999) 1.86
Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens. Eur Urol (1998) 1.73
Is transurethral resection of the prostate still justified? BJU Int (1999) 1.69
Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res (1995) 1.65
A multicenter, double-blind, randomized, parallel group study comparing polyvinyl chloride and polyvinyl chloride-free catheter materials. J Urol (2009) 1.63
High-grade prostate cancer is associated with low serum testosterone levels. Prostate (2001) 1.59
Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest (1992) 1.57
Urinary incontinence in both sexes: prevalence rates and impact on quality of life and sexual life. Neurourol Urodyn (2000) 1.55
EAU Guidelines on benign prostatic hyperplasia (BPH). Eur Urol (2001) 1.46
[The testis as eutopic production site of human growth hormone, placental lactogen and prolactin: possible autocrine/paracrine effects on testicular function]. Wien Klin Wochenschr (1996) 1.39
Diagnostic accuracy of DNA image cytometry and urinary cytology with cells from voided urine in the detection of bladder cancer. Urology (2000) 1.38
Tissue ablation in benign prostatic hyperplasia with high intensity focused ultrasound. J Urol (1994) 1.26
Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer. Br J Urol (1998) 1.21
Urodynamic assessment of patients with acute urinary retention: is treatment failure after prostatectomy predictable? J Urol (1997) 1.21
Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: is prostate cancer detection compromised in patients receiving long-term dialysis? Urology (1999) 1.18
Morphology of tissue destruction induced by focused ultrasound. Eur Urol (1993) 1.13
Urolithiasis in allograft kidneys. Urology (2002) 1.13
The aging lower urinary tract: a comparative urodynamic study of men and women. Urology (1998) 1.13
Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol (1999) 1.13
Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol (2001) 1.11
Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis--a prospective randomized study. Br J Urol (1994) 1.11
High expression of a CD38-like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease. J Urol (1995) 1.10
Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol (1997) 1.09
Tolerability of high energy transurethral microwave thermotherapy with topical urethral anesthesia: results of a prospective, randomized, single-blinded clinical trial. J Urol (1998) 1.09
Insulin-like growth factors and prostate cancer. World J Urol (2001) 1.09
Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol (1998) 1.07
Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem (1999) 1.07
Cross-sectional study of nocturia in both sexes: analysis of a voluntary health screening project. Urology (2000) 1.06
Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate. Prostate (1998) 1.06
Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem (1996) 1.06
Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months. Urology (2001) 1.06
PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology (1999) 1.05
Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk. Br J Cancer (2003) 1.05
Late sequelae of the management of ureteral calculi with the ureterorenoscope. J Urol (1986) 1.05
Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study. Urology (2000) 1.03
Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol (1998) 1.02
Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection. Urology (1999) 1.00
Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study. Prostate (2001) 1.00
Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol (1999) 1.00
Transrenal ureteral embolization. Radiology (1979) 0.99
Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate (2001) 0.99
Polymorphisms of glutathione-S-transferase genes (GSTP1, GSTM1 and GSTT1) and prostate-cancer risk. Int J Cancer (2001) 0.99
Impact of different sized catheters on pressure-flow studies in patients with benign prostatic hyperplasia. Neurourol Urodyn (1996) 0.98
Transcatheter embolization of the kidney with butyl-2-cyanoacrylate: experimental and clinical results. Cardiovasc Radiol (1978) 0.98
Spontaneous nontraumatic rupture of a contracted kidney with subcapsular and perirenal hematoma in a patient receiving chronic hemodialysis. Urology (1997) 0.98
Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Urol (1994) 0.98
mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin Cancer Res (2000) 0.98
Extracorporeal ablation of renal tumours with high-intensity focused ultrasound. BJU Int (2005) 0.97
Interrelationships of bladder compliance with age, detrusor instability, and obstruction in elderly men with lower urinary tract symptoms. Neurourol Urodyn (1999) 0.97
Can total and transition zone volume of the prostate determine whether to perform a repeat biopsy? Urology (2003) 0.95
Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol (1999) 0.95
Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. J Urol (2000) 0.95
Intracavernous injection of prostaglandin E1 in impotent men. J Urol (1988) 0.94
Is obstruction predictable by clinical evaluation in patients with lower urinary tract symptoms? Br J Urol (1997) 0.92
Modified laparoscopic nephroureterectomy for treatment of upper urinary tract transitional cell cancer is not associated with an increased risk of tumour recurrence. Eur Urol (2003) 0.92
Prostatic tissue ablation by transrectal high intensity focused ultrasound: histological impact and clinical application. Ultrason Sonochem (1997) 0.92
Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance? Eur Urol (2004) 0.92
Expression of the cell cycle proteins p21, p27, and pRb in clear cell renal cell carcinoma and their prognostic significance. Urology (2001) 0.92
Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia. J Urol (1999) 0.92
Prostate cancer in Austria: impact of prostate-specific antigen test on incidence and mortality. Eur J Cancer Prev (2001) 0.92
Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment. Int J Impot Res (2007) 0.91
Is penile atherosclerosis the link between erectile dysfunction and cardiovascular risk? An autopsy study. Int J Impot Res (2012) 0.91
Intrarenal access: effects on renal function and morphology. Br J Urol (1980) 0.91
Is one set of sextant biopsies enough to rule out prostate Cancer? Influence of transition and total prostate volumes on prostate cancer yield. Eur Urol (2000) 0.91
Risk factors for lower urinary tract symptoms in elderly men. For the Prostate Study Group of the Austrian Society of Urology. Eur Urol (2000) 0.91
Health care in Austria. Universal access, national health insurance, and private health care. JAMA (1993) 0.91
Tissue ablation in benign prostatic hyperplasia with high-intensity focused ultrasound. Eur Urol (1993) 0.91
Serial tissue polypeptide specific antigen determination in the followup of hormone treated carcinoma of the prostate. J Urol (1997) 0.90